The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Tyrosine Kinases as Targets for Cancer Therapy
Open accessAbstract
Tyrosine kinases, enzymes that catalyze the transfer of phosphate from ATP to tyrosine residues in polypeptides, are ubiquitous, numerous, and of considerable clinical interest because they participate in the development of cancer and have become choice targets for therapeutic intervention. This comprehensive review discusses the molecular and clinical aspects of tyrosine kinases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,830
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., & Misawa, S. (1996) · PubMed · Cited by 1,162
Golub, T. R., Barker, G. F., Lovett, M., & Gilliland, D. G. (1994) · Cell · doi:10.1016/0092-8674(94)90322-0 · Cited by 1,155
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,150
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Rubin, B. P., Singer, S., Tsao, C., Duensing, A. U., Lux, M. L., Ruiz, R., Hibbard, M. K., Chen, C. J., Xiao, S., Tuveson, D. A., et al. (2001) · PubMed · Cited by 959
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 948
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C., Knezevich, S. R., Huntsman, D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L., Carneiro, F., MacPherson, N., Horsman, D., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 911
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., & Kanayama, Y. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116761 · Cited by 816
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
Knezevich, S. R., McFadden, D. E., Tao, W., Lim, J. F., & Sorensen, P. H. B. (1998) · Nature Genetics · doi:10.1038/ng0298-184 · Cited by 800
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Han, S.-W., Kim, T.-Y., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D.-Y., Kim, J. H., Kim, D.-W., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 768
Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 765
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 740
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells
Irish, J. M., Hovland, R., Krutzik, P. O., Perez, O. D., Bruserud, Ø., Gjertsen, B. T., & Nolan, G. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.028 · Cited by 684
Stone, R. M., DeAngelo, D. J., Klimek, V., Galinsky, I., Estey, E., Nimer, S. D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., et al. (2005) · Blood · doi:10.1182/blood-2004-03-0891 · Cited by 657
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637
Smith, B. D., Levis, M., Beran, M., Giles, F., Kantarjian, H., Berg, K., Murphy, K. M., Dauses, T., Allebach, J., & Small, D. (2004) · Blood · doi:10.1182/blood-2003-11-3775 · Cited by 632
Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020150 · Cited by 630
Weisberg, E., Boulton, C., Kelly, L. M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D. G., & Griffin, J. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00069-7 · Cited by 599
Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
Nishida, T., Hirota, S., Taniguchi, M., Hashimoto, K., Isozaki, K., Nakamura, H., Kanakura, Y., Tanaka, T., Takabayashi, A., Matsuda, H., et al. (1998) · Nature Genetics · doi:10.1038/1209 · Cited by 586
Simon, M.-P., Pedeutour, F., Sirvent, N., Grosgeorge, J., Minoletti, F., Coindre, J.-M., Terrier-Lacombe, M.-J., Mandahl, N., Craver, R., Blin, N., et al. (1997) · Nature Genetics · doi:10.1038/ng0197-95 · Cited by 535
Ma, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E., & Salgia, R. (2003) · PubMed · Cited by 516
The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain
Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M., Lu, F., Lippke, J., & Saxena, K. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00505-7 · Cited by 499
Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers
Bardelli, A., Parsons, D. W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., et al. (2003) · Science · doi:10.1126/science.1082596 · Cited by 484
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia
Graux, C., Cools, J., Melotte, C., Quentmeier, H., Ferrando, A., Levine, R., Vermeesch, J. R., Stul, M., Dutta, B., Boeckx, N., et al. (2004) · Nature Genetics · doi:10.1038/ng1425 · Cited by 433
Evans, W. K. (. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.08.002 · Cited by 405
Pardanani, A., Ketterling, R. P., Brockman, S. R., Flynn, H. C., Paternoster, S. F., Shearer, B. M., Reeder, T. L., Li, C.-Y., Cross, N. C. P., Cools, J., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1627 · Cited by 393
Klion, A. D., Noel, P., Akin, C., Law, M. A., Gilliland, D. G., Cools, J., Metcalfe, D. D., & Nutman, T. B. (2003) · Blood · doi:10.1182/blood-2003-01-0006 · Cited by 386
Chen, L. L., Trent, J. C., Wu, E. F., Fuller, G. N., Ramdas, L., Zhang, W., Raymond, A. K., Prieto, V. G., Oyedeji, C. O., Hunt, K. K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0085 · Cited by 339
Rowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia
Golub, T. R., Goga, A., Barker, G. F., Afar, D. E. H., McLaughlin, J., Bohlander, S. K., Rowley, J. D., Witte, O. N., & Gilliland, D. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4107 · Cited by 324
KIT Mutations Are Common in Testicular Seminomas
Kemmer, K., Corless, C. L., Fletcher, J. A., McGreevey, L., Haley, A., Griffith, D., Cummings, O. W., Wait, C., Town, A., & Heinrich, M. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63120-3 · Cited by 322
Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., & Stiles, C. D. (2000) · PubMed · Cited by 310
Kottaridis, P. D., Gale, R. E., Langabeer, S. E., Frew, M. E., Bowen, D. T., & Linch, D. C. (2002) · Blood · doi:10.1182/blood-2002-02-0420 · Cited by 307
Fusion of ETV6 to Neurotrophin-3 Receptor TRKC in Acute Myeloid Leukemia With t(12;15)(p13;q25)
Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1355 · Cited by 281
Casali, P. G., Messina, A., Stacchiotti, S., Tamborini, E., Crippa, F., Gronchi, A., Orlandi, R., Ripamonti, C., Spreafico, C., Bertieri, R., et al. (2004) · Cancer · doi:10.1002/cncr.20618 · Cited by 268
c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia
Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I., & Reilly, J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01449.x · Cited by 262
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Dührsen, U., Flasshove, M., Ottmann, O. G., Jung, W., Cavalli, F., et al. (2003) · Blood · doi:10.1182/blood-2002-10-2998 · Cited by 262
Greco, A., Pierotti, M. A., Bongarzone, I., Pagliardini, S., Lanzi, C., & Porta, G. (1992) · PubMed · Cited by 226
FMS mutations in myelodysplastic, leukemic, and normal subjects.
Ridge, S. A., Worwood, M., Oscier, D., Jacobs, A., & Padua, R. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1377 · Cited by 220
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
Gumireddy, K., Baker, S. J., Cosenza, S. C., John, P., Kang, A. D., Robell, K. A., Reddy, M. V. R., & Reddy, E. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408283102 · Cited by 220
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00108-9 · Cited by 216
Charest, A., Lane, K., McMahon, K., Park, J., Preisinger, E., Conroy, H., & Housman, D. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10207 · Cited by 211
Macdonald, D., Reiter, A., & Cross, N. C. P. (2002) · Acta Haematologica · doi:10.1159/000046639 · Cited by 210
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
Zheng, R., Levis, M., Piloto, O., Brown, P., Baldwin, B. R., Gorin, N. C., Beran, M., Zhu, Z., Ludwig, D., Hicklin, D., et al. (2004) · Blood · doi:10.1182/blood-2003-06-1969 · Cited by 205
Phase II study of imatinib in patients with small cell lung cancer.
Johnson, B. E., Fischer, T. H., Fischer, B., Dunlop, D. J., Rischin, D., Silberman, S., Kowalski, M. O., Sayles, D., Dimitrijević, S., Fletcher, C. D. �., et al. (2003) · PubMed · Cited by 192
Zermati, Y., De Sepulveda, P., Féger, F., Létard, S., Kersual, J., Castéran, N., Gorochov, G., Dy, M., Ribadeau Dumas, A., Dorgham, K., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206120 · Cited by 191
Soman, N. R., Correa, P., Ruiz, B. A., & Wogan, G. N. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4892 · Cited by 190
Chen, J., DeAngelo, D. J., Kutok, J. L., Williams, I. R., Lee, B. H., Wadleigh, M., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404438101 · Cited by 171
Gilliland, D. G., & Tallman, M. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00081-8 · Cited by 169
Autoinhibition of Bcr-Abl through Its SH3 Domain
Smith, K. M., Yacobi, R., & Van Etten, R. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00274-0 · Cited by 162
Self-citationc-kit Expression in Pediatric Solid Tumors: A Comparative Immunohistochemical Study
Smithey, B. E., Pappo, A. S., & Hill, D. A. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200204000-00011 · Cited by 160
Kuno, Y., Abe, A., Emi, N., Iida, M., Yokozawa, T., Towatari, M., Tanimoto, M., & Saito, H. (2001) · Blood · doi:10.1182/blood.v97.4.1050 · Cited by 147
Improving the evaluation of new cancer treatments: challenges and opportunities
Rothenberg, M. L., Carbone, D. P., & Johnson, D. H. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1047 · Cited by 145
Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia
Kindler, T., Breitenbuecher, F., Marx, A., Beck, J., Heß, G., Weinkauf, B., Duyster, J., Peschel, C., Kirkpatrick, C. J., Theobald, M., et al. (2004) · Blood · doi:10.1182/blood-2003-06-2071 · Cited by 142
Zhao, J., Roth, J., Bode‐Lesniewska, B., Pfaltz, M., Heitz, P. U., & Komminoth, P. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10035 · Cited by 132
Requirement for Abl Kinases in T Cell Receptor Signaling
Zipfel, P. A., Zhang, W., Quiroz, M. E., & Pendergast, A. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.07.021 · Cited by 118
McGary, E. C., WEBER, K. L., Mills, L., Doucet, M., Lewis, V., Lev, D. C., Fidler, I. J., & Bar‐Eli, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1101 · Cited by 113
Cazzaniga, G., Tosi, S., Aloisi, A., Giudici, G., Daniotti, M., Pioltelli, P. E., Kearney, L., & Biondi, A. (1999) · Blood · doi:10.1182/blood.v94.12.4370 · Cited by 112
Liu, Q., Schwaller, J., Kutok, J. L., Cain, D., Aster, J. C., Williams, I. R., & Gilliland, D. G. (2000) · The EMBO Journal · doi:10.1093/emboj/19.8.1827 · Cited by 110
Arteaga, C. L., & Baselga, J. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.028 · Cited by 95
Focus on myeloproliferative diseases and myelodysplastic syndromes
Etten, R. A. V., & Shannon, K. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.004 · Cited by 93
Watanabe, D., Ezoe, S., Fujimoto, M., Kimura, A., Saito, Y., Nagai, H., Tachibana, I., Matsumura, I., Tanaka, T., Kanegane, H., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05107.x · Cited by 89
Holdhoff, M., Kreuzer, K., Appelt, C., Scholz, R., Na, I., Hildebrandt, B., Riess, H. B., Jordan, A., Schmidt, C. A., Etten, R. A. V., et al. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2004.11.006 · Cited by 80
Molecularly targeted treatment for dermatofibrosarcoma protuberans
McArthur, G. A. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.03.038 · Cited by 77
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Wadleigh, M., DeAngelo, D. J., Griffin, J. D., & Stone, R. M. (2004) · Blood · doi:10.1182/blood-2003-11-3896 · Cited by 74
Schaefer, K., Brachwitz, K., Wai, D., Braun, Y., Diallo, R. I., Korsching, E., Eisenacher, M., Voß, R., van Valen, F., Baer, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0809 · Cited by 74
Wong, S., McLaughlin, J., Cheng, D., Zhang, C., Shokat, K. M., & Witte, O. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407061101 · Cited by 72
Cruz, J., Reis-Filho, J. S., Silva, P., & Lopes, J. M. (2003) · Oncology · doi:10.1159/000071207 · Cited by 72
Tamborini, E., Bonadiman, L., Greco, A., Gronchi, A., Riva, C., Bertulli, R., Casali, P. G., Pierotti, M. A., & Pilotti, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0059 · Cited by 63
Monoclonal antibody therapy for breast cancer: Herceptin
Finn, R. S., & Slamon, D. J. (2003) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(03)21010-3 · Cited by 39
c-Abl regulation: a tail of two lipids
Etten, R. A. V. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00528-1 · Cited by 38
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Metadata
- Authors
- Krause, D. S., & Van Etten, R. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-14
- Volume
- 353
- Issue
- 2
- Pages
- 172-187
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164452916
- Cited by
- 1,387
- References
- 112
- FWCI
- 59.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.